Characteristics of stage II and III patients with mismatch repair (MMR) competent versus MMR deficient tumours
| MMR competent (n = 452) | MMR deficient (n = 53) | p Value | |
|---|---|---|---|
| p values were calculated using the log rank value. | |||
| MMR, mismatch repair; 5-FU, 5-fluorouracil; 95% CI, 95% confidence interval. | |||
| Age (y) | 70.8 (10.7) | 69.2 (14.2) | 0.3 |
| Sex (n (%)) | 0.02 | ||
| Males | 267 (59) | 19 (36) | |
| Females | 185 (41) | 34 (64) | |
| Adjuvant 5-FU chemotherapy (%) | 241 (53) | 19 (36) | 0.02 |
| Vital status (n (%)) | |||
| Dead | 87 (19) | 8 (15) | 0.4 |
| Recurrence (n (%)) | 103 (23) | 7 (13) | 0.4 |
| Survival (days) (95% CI) | 940 (910–970) | 940 (853–1028) | 0.5 |
| Disease free survival (days) (95% CI) | 884 (854–915) | 970 (897–1042) | 0.1 |